ABCG2 and SLCO1B1 gene polymorphisms in the Croatian population

References

• [CPIC] Clinical Pharmacogenetics Implementation Consortium 2022. [accessed 2022 Feb 22]. www.cpicpgx.org/.
   Google Scholar
• [DPWG] Dutch Pharmacogenetics Working Group 2022. Pharmacogenetic recommendation text 20220201. [accessed 2022 March 23]. https://www.knmp.nl/media/1058.
   Google Scholar
• [EMA] European Medicines Agency 2012., London, UK: guideline on the investigation of drug interactions CPMP/EWP/560/95/rev. 1 Corr. 2**. [accessed 2022 March 22]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf.
   Google Scholar
• [FDA] 2017. US Food and Drug Administration: guidance for industry: drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations. [accessed 2022 March 22]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf.
   Google Scholar
• [FDA] US Food and Drug Administration 2021. Table of pharmacogenomic biomarkers in drug labels. [accessed 20022 March 22]. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm.
   Google Scholar
• [gnomAD] Genome Aggregation Database 2022. [accessed 2022 March 22]. https://gnomad.broadinstitute.org/.
   Google Scholar
• [PharmGKB] The Pharmacogenomics Knowledgebase 2021. Drug label annotations. [accessed 2022 Feb 22]. https://www.pharmgkb.org/labelAnnotations.
   Google Scholar
• Bielen L, Kralj I, Ćurčić E, Vodanović M, Boban A, Božina N. 2018. Acute kidney injury, agranulocytosis, drug-induced liver injury, and posterior reversible encephalopathy syndrome caused by high-dose methotrexate-possible role of low activity ABC and SLC drug transporters. Eur J Clin Pharmacol. 74(9):1191–1192.
   PubMed Web of Science ®Google Scholar
• Bińkowski J, Miks S. 2018. Gene-Calc [Computer software]. www.gene-calc.pl.
   Google Scholar
• Bruckmueller H, Cascorbi I. 2021a. ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding? Expert Opin Drug Metab Toxicol. 17(4):369–396.
   PubMed Web of Science ®Google Scholar
• Bruckmueller H, Cascorbi I. 2021b. Drug-Drug-Gene Interactions: a Call for Clinical Consideration. Clin Pharmacol Ther. 110(3):549–551.
   PubMed Web of Science ®Google Scholar
• Bruhn O, Cascorbi I. 2014. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol. 10(10):1337–1354.
   PubMed Web of Science ®Google Scholar
• Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, Visscher H, et al. 2012. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 12(3):233–237.
   PubMed Web of Science ®Google Scholar
• Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, et al. 2022. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 111(5):1007–1021.
   PubMed Web of Science ®Google Scholar
• Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, et al. 2006. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 98(23):1739–1742.
   PubMedGoogle Scholar
• Donnelly LA, Doney AS, Tavendale R, Lang CC, Pearson ER, Colhoun HM, McCarthy MI, Hattersley AT, et al. 2011. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther. 89(2):210–216.
   PubMed Web of Science ®Google Scholar
• Ehmann F, Caneva L, Prasad K, Paulmichl M, Maliepaard M, Llerena A, Ingelman-Sundberg M, Papaluca-Amati M. 2015. Pharmacogenomic information in drug labels: european Medicines Agency perspective. Pharmacogenomics J. 15(3):201–210.
   PubMed Web of Science ®Google Scholar
• Elsby R, Hilgendorf C, Fenner K. 2012. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it’s not just about OATP1B1. Clin Pharmacol Ther. 92(5):584–598.
   PubMed Web of Science ®Google Scholar
• Endres CJ, Hsiao P, Chung FS, Unadkat JD. 2006. The role of transporters in drug interactions. Eur J Pharm Sci. 27(5):501–517.
   PubMed Web of Science ®Google Scholar
• Fohner AE, Brackman DJ, Giacomini KM, Altman RB, Klein TE. 2017. PharmGKB summary: very important pharmacogene information for ABCG2. Pharmacogenet Genomics. 27(11):420–427.
   PubMed Web of Science ®Google Scholar
• Franke RM, Gardner ER, Sparreboom A. 2010. Pharmacogenetics of drug transporters. Curr Pharm Des. 16(2):220–230.
   PubMed Web of Science ®Google Scholar
• Furukawa T, Wakabayashi K, Tamura A, Nakagawa H, Morishima Y, Osawa Y, Ishikawa T. 2009. Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations. Pharm Res. 26(2):469–479.
   PubMed Web of Science ®Google Scholar
• Ganoci L, Trkulja V, Živković M, Božina T, Šagud M, Lovrić M, Božina N. 2021. ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone. Prog Neuropsychopharmacol Biol Psychiatry. 104:110042.
   PubMed Web of Science ®Google Scholar
• Gessner A, König J, Fromm MF. 2019. Clinical Aspects of Transporter-Mediated Drug-Drug Interactions. Clin Pharmacol Ther. 105(6):1386–1394.
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Balimane PV, Cho SK, Eadon M, Edeki T, Hillgren KM, Huang SM, International Transporter Consortium, et al. 2013. International Transporter Consortium commentary on clinically important transporter polymorphisms. Clin Pharmacol Ther. 94(1):23–26.
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, International Transporter Consortium, et al. 2010. Membrane transporters in drug development. Nat Rev Drug Discov. 9(3):215–236.
   PubMed Web of Science ®Google Scholar
• Gotanda K, Tokumoto T, Hirota T, Fukae M, Ieiri I. 2015. Sulfasalazine disposition in a subject with 376C > T (nonsense mutation) and 421C > A variants in the ABCG2 gene. Br J Clin Pharmacol. 80(5):1236–1237.
   PubMed Web of Science ®Google Scholar
• Grapci AD, Dimovski AJ, Kapedanovska A, Vavlukis M, Eftimov A, Matevska Geshkovska N, Labachevski N, et al. 2015. Frequencies of single-nucleotide polymorphisms and haplotypes of the SLCO1B1 gene in selected populations of the western balkans. Balkan J Med Genet. 18(1):5–21.
   PubMed Web of Science ®Google Scholar
• Gregory BJ, Chen SM, Murphy MA, Atchley DH, Kamdem LK. 2017. Impact of the OATP1B1 c.521T > C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy post-menopausal female volunteers. J Clin Pharm Ther. 42(5):547–553.
   PubMed Web of Science ®Google Scholar
• Gulilat M, Keller D, Linton B, Pananos AD, Lizotte D, Dresser GK, Alfonsi J, et al. 2020. Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. J Thromb Thrombolysis. 49(2):294–303.
   PubMed Web of Science ®Google Scholar
• Hagenbuch B, Meier PJ. 2003. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta. 1609(1):1–18.
   PubMed Web of Science ®Google Scholar
• Hagenbuch B, Meier PJ. 2004. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 447(5):653–665.
   PubMed Web of Science ®Google Scholar
• Heyes N, Kapoor P, Kerr ID. 2018. Polymorphisms of the Multidrug Pump ABCG2: a Systematic Review of Their Effect on Protein Expression, Function, and Drug Pharmacokinetics. Drug Metab Dispos. 46(12):1886–1899.
   PubMed Web of Science ®Google Scholar
• Hillgren KM, Keppler D, Zur AA, Giacomini KM, Stieger B, Cass CE, Zhang L, International Transporter Consortium 2013. Emerging transporters of clinical importance: an update from the International Transporter Consortium. Clin Pharmacol Ther. 94(1):52–63.
   PubMed Web of Science ®Google Scholar
• Hira D, Terada T. 2018. BCRP/ABCG2 and high-alert medications: biochemical, pharmacokinetic, pharmacogenetic, and clinical implications. Biochem Pharmacol. 147:201–210.
   PubMed Web of Science ®Google Scholar
• Hirota T, Fujita Y, Ieiri I. 2020. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol. 16(9):809–822.
   PubMed Web of Science ®Google Scholar
• Hofman J, Sorf A, Vagiannis D, Sucha S, Kammerer S, Küpper JH, Chen S, et al. 2019. Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes. Mol Pharm. 16(11):4436–4450.
   PubMedGoogle Scholar
• Horsey AJ, Cox MH, Sarwat S, Kerr ID. 2016. The multidrug transporter ABCG2: still more questions than answers. Biochem Soc Trans. 44(3):824–830.
   PubMed Web of Science ®Google Scholar
• Huang SM, Zhang L, Giacomini KM. 2010. The International Transporter Consortium: a collaborative group of scientists from academia, industry, and the FDA. Clin Pharmacol Ther. 87(1):32–36.
   PubMed Web of Science ®Google Scholar
• Jada SR, Xiaochen S, Yan LY, Xiaoqiang X, Lal S, Zhou SF, Ooi LL, Chowbay B. 2007. Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations. Eur J Clin Pharmacol. 63(6):555–563.
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Niemi M. 2009. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 158(3):693–705.
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M. 2009. Different effects of the ABCG2 c.421C > A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics. 10(10):1617–1624.
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. 2009. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 86(2):197–203.
   PubMed Web of Science ®Google Scholar
• Klaassen CD, Aleksunes LM. 2010. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev. 62(1):1–96.
   PubMed Web of Science ®Google Scholar
• Klarica Domjanović I, Lovrić M, Trkulja V, Petelin-Gadže Ž, Ganoci L, Čajić I, Božina N. 2018. Interaction between ABCG2 421C > A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy. Br J Clin Pharmacol. 84(9):2106–2119.
   PubMed Web of Science ®Google Scholar
• Kondo C, Suzuki H, Itoda M, Ozawa S, Sawada J, Kobayashi D, Ieiri I, et al. 2004. Functional analysis of SNPs variants of BCRP/ABCG2. Pharm Res. 21(10):1895–1903.
   PubMed Web of Science ®Google Scholar
• Lähteenmäki J, Vuorinen A‐L, Pajula J, Harno K, Lehto M, Niemi M, Gils M. 2021. Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users. Clin Pharma and Therapeutics. 110(3):768–776.
   PubMed Web of Science ®Google Scholar
• Launay-Vacher V, Izzedine H, Deray G. 2005. Statins’ dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. Int J Cardiol. 101(1):9–17.
   PubMed Web of Science ®Google Scholar
• Lazarou J, Pomeranz BH, Corey PN. 1998. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 279(15):1200–1205.
   PubMed Web of Science ®Google Scholar
• Li LM, Chen L, Deng GH, Tan WT, Dan YJ, Wang RQ, Chen WS. 2012. SLCO1B1 *15 haplotype is associated with rifampin-induced liver injury. Mol Med Rep. 6(1):75–82.
   PubMed Web of Science ®Google Scholar
• Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, SEARCH Collaborative Group, et al. 2008. SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med. 359(8):789–799.
   PubMed Web of Science ®Google Scholar
• Litjens CHC, van den Heuvel JJMW, Russel FGM, Aarnoutse RE, Te Brake LHM, Koenderink JB. 2020. Rifampicin Transport by OATP1B1 Variants. Antimicrob Agents Chemother. 64(10):e00955-20.
   PubMed Web of Science ®Google Scholar
• Low SK, Fukunaga K, Takahashi A, Matsuda K, Hongo F, Nakanishi H, Kitamura H, et al. 2016. Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction. PLoS One. 11(2):e0148177.
   PubMed Web of Science ®Google Scholar
• Luo JQ, He FZ, Wang ZM, Sun NL, Wang LY, Tang GF, Liu MZ, et al. 2015. SLCO1B1 Variants and Angiotensin Converting Enzyme Inhibitor (Enalapril)-Induced Cough: a Pharmacogenetic Study. Sci Rep. 5:5:17253.
   PubMed Web of Science ®Google Scholar
• Malfará BN, Benzi JRL, de Oliveira Filgueira GC, Zanelli CF, Duarte G, de Carvalho Cavalli R, de Moraes NV. 2019. ABCG2 c.421C > A polymorphism alters nifedipine transport to breast milk in hypertensive breastfeeding women. Reprod Toxicol. 85:1–5.
   PubMed Web of Science ®Google Scholar
• Malki MA, Pearson ER. 2020. Drug-drug-gene interactions and adverse drug reactions. Pharmacogenomics J. 20(3):355–366.
   PubMed Web of Science ®Google Scholar
• Mao Q, Unadkat JD. 2015. Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport–an update. Aaps J. 17(1):65–82.
   PubMed Web of Science ®Google Scholar
• Matsuo H, Takada T, Ichida K, Nakamura T, Nakayama A, Suzuki H, Hosoya T, Shinomiya N. 2011. ABCG2/BCRP dysfunction as a major cause of gout. Nucleosides Nucleotides Nucleic Acids. 30(12):1117–1128.
   PubMed Web of Science ®Google Scholar
• Merćep I, Radman I, Trkulja V, Božina T, Šimičević L, Budimir E, Ganoci L, Božina N. 2022. Loss of function polymorphisms in SLCO1B1 (c.521T > C, rs4149056) and ABCG2 (c.421C > A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study. Eur J Clin Pharmacol. 78(2):227–236.
   PubMed Web of Science ®Google Scholar
• Miroševic Skvrce N, Božina N, Zibar L, Barišic I, Pejnovic L, Macolic Šarinic V. 2013. CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case-control study. Pharmacogenomics. 14(12):1419–1431.
   PubMed Web of Science ®Google Scholar
• Mirošević Skvrce N, Macolić Šarinić V, Šimić I, Ganoci L, Muačević Katanec D, Božina N. 2015. ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study. Pharmacogenomics. 16(8):803–815.
   PubMed Web of Science ®Google Scholar
• Moyer AM, de Andrade M, Faubion SS, Kapoor E, Dudenkov T, Weinshilboum RM, Miller VM. 2018. SLCO1B1 genetic variation and hormone therapy in menopausal women. Menopause. 25(8):877–882.
   PubMed Web of Science ®Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. 2011. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 63(1):157–181.
   PubMed Web of Science ®Google Scholar
• Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, Tsuji A, Yokoi T. 2002. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther. 302(2):804–813.
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Backman JT, Neuvonen PJ, Niemi M. 2006. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur J Clin Pharmacol. 62(6):409–415.
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. 2006. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 16(12):873–879.
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Neuvonen PJ, Niemi M. 2008. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics. 9(1):19–33.
   PubMed Web of Science ®Google Scholar
• Peričić M, Barać Lauc L, Martinović Klarić I, Janićijević B, Rudan P. 2005. Review of Croatian genetic heritage as revealed by mitochondrial DNA and Y chromosomal lineages. Croat Med J. 46(4):502–513.
   PubMed Web of Science ®Google Scholar
• Pericić M, Lauc LB, Klarić IM, Rootsi S, Janićijevic B, Rudan I, Terzić R, et al. 2005. High-resolution phylogenetic analysis of southeastern Europe traces major episodes of paternal gene flow among Slavic populations. Mol Biol Evol. 22(10):1964–1975.
   PubMed Web of Science ®Google Scholar
• Poirier A, Portmann R, Cascais AC, Bader U, Walter I, Ullah M, Funk C. 2014. The need for human breast cancer resistance protein substrate and inhibition evaluation in drug discovery and development: why, when, and how? Drug Metab Dispos. 42(9):1466–1477.
   PubMed Web of Science ®Google Scholar
• Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, Maxwell WD, McLeod HL, et al. 2014. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 96(4):423–428.
   PubMed Web of Science ®Google Scholar
• Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, Bates SE. 2009. ABCG2: a perspective. Adv Drug Deliv Rev. 61(1):3–13.
   PubMed Web of Science ®Google Scholar
• Roszkiewicz J, Michałek D, Ryk A, Swacha Z, Szmyd B, Smolewska E. 2021. SLCO1B1 variants as predictors of methotrexate-related toxicity in children with juvenile idiopathic arthritis. Scand J Rheumatol. 50(3):213–217.
   PubMed Web of Science ®Google Scholar
• Safar Z, Kis E, Erdo F, Zolnerciks JK, Krajcsi P. 2019. ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors. Expert Opin Drug Metab Toxicol. 15(4):313–328.
   PubMed Web of Science ®Google Scholar
• Sakiyama M, Matsuo H, Takada Y, Nakamura T, Nakayama A, Takada T, Kitajiri S, et al. 2014. Ethnic differences in ATP-binding cassette transporter, sub-family G, member 2 (ABCG2/BCRP): genotype combinations and estimated functions. Drug Metab Pharmacokinet. 29(6):490–492.
   PubMed Web of Science ®Google Scholar
• Scarpini F, Cappellone R, Auteri A, Puccetti L. 2012. Role of genetic factors in statins side-effects. Cardiovasc Hematol Disord Drug Targets. 12(1):35–43.
   PubMedGoogle Scholar
• Schulte RR, Choi L, Utreja N, Van Driest SL, Stein CM, Ho RH. 2021. Effect of SLCO1B1 Polymorphisms on High-Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma. Clin Transl Sci. 14(1):343–353.
   PubMed Web of Science ®Google Scholar
• Shu Q, Fan Q, Hua B, Liu H, Wang S, Liu Y, Yao Y, et al. 2021. Influence of SLCO1B1 521T > C, UGT2B7 802C > T and IMPDH1 -106G > A Genetic Polymorphisms on Mycophenolic Acid Levels and Adverse Reactions in Chinese Autoimmune Disease Patients. Pharmgenomics Pers Med. 14:713–722.
   PubMed Web of Science ®Google Scholar
• Skvrce NM, Krivokapić S, Božina N. 2020. Implementation of pharmacogenomics in product information. Pharmacogenomics. 21(7):443–448.
   PubMed Web of Science ®Google Scholar
• Song G, Chung JE, Yee J, Lee KE, Park K, Gwak HS. 2021. Effects of SLCO1B1 and SLCO1B3 Genetic Polymorphisms on Valsartan Pharmacokinetics in Healthy Korean Volunteers. JPM. 11(9):862.
   Google Scholar
• Song Y, Lim HH, Yee J, Yoon HY, Gwak HS. 2022. The Association between ABCG2 421C > A (rs2231142) Polymorphism and Rosuvastatin Pharmacokinetics: A Systematic Review and Meta-Analysis. Pharmaceutics. 14(3):501.
   PubMed Web of Science ®Google Scholar
• Svedberg A, Jacobs L, Vikingsson S, Gréen H. 2020. The influence of ABCG2 polymorphism on erlotinib efflux in the K562 cell line. Pharmacol Res Perspect. 8(2):e00581.
   PubMed Web of Science ®Google Scholar
• The 1000 Genomes database 2021. The 1000 Genomes database [accessed Feb 21]. http://www.1000genomes.org/.
   Google Scholar
• Tirona RG, Leake BF, Merino G, Kim RB. 2001. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem. 276(38):35669–35675.
   PubMed Web of Science ®Google Scholar
• Tirona RG. 2011. Molecular mechanisms of drug transporter regulation. Handb Exp Pharmacol. 201:373–402.
   PubMedGoogle Scholar
• Toyoda Y, Takada T, Suzuki H. 2019. Inhibitors of Human ABCG2: from Technical Background to Recent Updates With Clinical Implications. Front Pharmacol. 10:208.
   PubMed Web of Science ®Google Scholar
• Treiber A, Schneiter R, Häusler S, Stieger B. 2007. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 35(8):1400–1407.
   PubMed Web of Science ®Google Scholar
• Tsamandouras N, Guo Y, Wendling T, Hall S, Galetin A, Aarons L. 2017. Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population. Pharmacogenet Genomics. 27(1):27–38.
   PubMed Web of Science ®Google Scholar
• Turner RM, Fontana V, FitzGerald R, Morris AP, Pirmohamed M. 2020. Investigating the clinical factors and comedications associated with circulating levels of atorvastatin and its major metabolites in secondary prevention. Br J Clin Pharmacol. 86(1):62–74.
   PubMed Web of Science ®Google Scholar
• Turner RM, Radman I, Bozina N, Alfirevic A. 2020. Pharmacogenetics and statin-related myopathy: what do we know? Pharmacogenomics. 21(12):821–825.
   PubMed Web of Science ®Google Scholar
• Turongkaravee S, Jittikoon J, Lukkunaprasit T, Sangroongruangsri S, Chaikledkaew U, Thakkinstian A. 2021. A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy. Pharmacogenomics J. 21(3):296–307.
   PubMed Web of Science ®Google Scholar
• Ueshima S, Hira D, Kimura Y, Fujii R, Tomitsuka C, Yamane T, Tabuchi Y, et al. 2018. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. Br J Clin Pharmacol. 84(6):1301–1312.
   PubMed Web of Science ®Google Scholar
• Verbeurgt P, Mamiya T, Oesterheld J. 2014. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. Pharmacogenomics. 15(5):655–665.
   PubMed Web of Science ®Google Scholar
• Wen X, Kozlosky D, Zhang R, Doherty C, Buckley B, Barrett E, Aleksunes LM. 2021. BCRP/ABCG2 Transporter Regulates Accumulation of Cadmium in Kidney Cells: role of the Q141K Variant in Modulating Nephrotoxicity. Drug Metab Dispos. 49(8):629–637.
   PubMed Web of Science ®Google Scholar
• Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Clinical Pharmacogenomics Implementation Consortium (CPIC), et al. 2012. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 92(1):112–117.
   PubMed Web of Science ®Google Scholar
• Xiao Q, Zhou Y, Lauschke VM. 2020. Ethnogeographic and inter-individual variability of human ABC transporters. Hum Genet. 139(5):623–646.
   PubMed Web of Science ®Google Scholar
• Yee SW, Brackman DJ, Ennis EA, Sugiyama Y, Kamdem LK, Blanchard R, Galetin A, et al. 2018. Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium. Clin Pharmacol Ther. 104(5):803–817.
   PubMed Web of Science ®Google Scholar
• Zamek-Gliszczynski MJ, Taub ME, Chothe PP, Chu X, Giacomini KM, Kim RB, Ray AS, International Transporter Consortium, et al. 2018. Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. Clin Pharmacol Ther. 104(5):890–899.
   PubMed Web of Science ®Google Scholar